Currently Viewing:
Newsroom
Currently Reading
AHIP Packages Healthcare Affordability Recommendations; ACA Enrollment Dips
November 14, 2018 – Allison Inserro
Higher BMI Decreases Risk of Breast Cancer in Premenopausal Women
November 14, 2018 – David Bai, PharmD
Provider Stigma Toward HIV Slows Prevention Goals
November 14, 2018 – Jaime Rosenberg
Most Patients With CF May Get Insufficient Antibiotics to Fight Lung Infections
November 14, 2018 – Jackie Syrop
Common Probiotic Stimulates Bone Formation in Mice, Study Says
November 14, 2018 – Allison Inserro
What We're Reading: Wildfire Health Emergency; New Express Scripts Formulary; Insurer Monopoly in Florida
November 14, 2018 – AJMC Staff
Which Patients With COPD Are Affected the Most by Extreme Weather?
November 14, 2018 – Allison Inserro
ANCHOR Study Finds High Adherence Rate in Patients With Hepatitis C Who Inject Opioids
November 13, 2018 – Surabhi Dangi-Garimella, PhD
Hoping to Fend Off FDA, Juul to Stop Selling Certain e-Cig Flavors, For Now
November 13, 2018 – Allison Inserro

Analysis Estimates Empagliflozin Will Add Years to Life for People With Type 2 Diabetes

Mary Caffrey
The analysis of data from EMPA-REG OUTCOME arrives as the FDA weighs the future of these large trials.
Results derived from the cardiovascular outcomes trial for empagliflozin suggest that the drug could extend life for people with type 2 diabetes (T2D), with greater benefits for those who start taking the drug at younger ages. The analysis appears in the journal Circulation, the official journal of the American Heart Association.

Using actuarial methods and assuming the benefits of empagliflozin remain constant, the team led by Harvard biostatistician Brian Claggett, PhD, estimated that the therapy could extend life by between 1 and 4.5 years. They made their calculations based on data gathered from 7020 people who took part in EMPA-REG OUTCOME, the first trial that showed a T2D therapy was not simply safe but also had cardiovascular benefits.

The trial showed a 38% relative risk reduction in cardiovascular death and a 32% risk reduction in all-cause mortality among those with T2D and cardiovascular disease. Empagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor, and since the publication of EMPA-REG OUTCOME, competitors in the class have reported cardiovascular benefits.

In this new analysis, the survival benefit was greater for younger patients and diminished compared with placebo as the study patients aged: The mean differences between patients taking empagliflozin and those taking placebo were 4.5 years at age 45, 3.1 years at age 50, 2.5 years at age 60, 2.0 years at age 70, and 1 year at age 80.

“For a 60-year-old living with type 2 diabetes, who has already had a cardiovascular event, previous studies estimate that life expectancy could be reduced by up to 12 years compared with someone of the same age without these conditions,” Claggett said in a statement. “This latest analysis estimates that empagliflozin could prolong such a person’s life span by, on average, 2.5 years.”

The findings come as an FDA advisory committee gets ready to weigh the future of large cardiovascular outcomes trials like EMPA-REG OUTCOME. A meeting is set for October 24-25 to discuss the trials, which were required after concerns over the safety of rosiglitazone.

A report in Diabetes Care, whose authors included some of the leading scientists who worked on these trials, notes that although the round of trials have revealed unanticipated benefits, the high costs involved must be considered.

Empagliflozin is sold as Jardiance by Boehringer-Ingelheim and Eli Lilly, which funded the study.

Reference

Claggett B, Lachin JM, Hantel S, et al. Long-term benefit of empagliflozin on life expectancy in patients with type 2 diabetes mellitus and established cardiovascular disease. Circulation. 2018;138(15):1599-1601.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!